A role for p16 inactivation is implicated in a wide variety of tumors, including melanoma, pancreatic and breast adenocarcinomas, squamous cell carcinoma of the head and neck, and mesotheliomas. This evidence concerns the gene CDKN2A and breast adenocarcinoma.